Karyotype evolution at progression. Karyotyping was performed at baseline and at the time of clinical disease progression (PD) and karyotypes were evaluated for complex karyotypes and the presence of deletion 17p (A). Karyotyping data from 27 of 60 (45.0%, CIT arm) and 59 of 98 patients (60.2%, venetoclax arms) with PD were available at progression. In the CIT arm, the fraction of patients with CKT increased from 7 of 27 (25.9%) to 12 of 27 (44.4%) between baseline (blue) and progression (dark blue). In the same time, the fraction of patients with CKT in the pooled venetoclax arms increased from 14 of 59 (23.7%, yellow) to 18 of 59 (30.5%, orange). The prevalence of del(17p) at the time of CLL progression was also higher in the CIT arm (14.8%) compared with the pooled venetoclax arms (0 patients). We also measured the median number of CA in patients who had clinical disease progression (B). In the CIT arm, the median number of CA increased from 2.0 at baseline (blue) to 3.4 at progression (dark blue). In the pooled venetoclax arms, the median number of CA was 2.0 both at baseline (yellow) and at progression (orange). del(17p), deletion 17p; PD, time point of clinical progression of CLL; ven, pooled venetoclax arms.